Lipid metabolism and Alzheimer's disease: Pathways and possibilities

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 3, 2009, Pages 331-338

  Saxena, Uday ^a  

^a Kareus Therapeutics   (United States)

Author keywords

A peptides; Alzheimer's disease; Amyloid plaque; Cholesterol; Lipid metabolism; Lipoproteins

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; CLIOQUINOL; GAMMA SECRETASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; HUMAN; LIPID METABOLISM; MEDICAL LITERATURE; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PROTEIN AGGREGATION; REVIEW; ANIMAL; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPID METABOLISM;

EID: 65549130578     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902738720     Document Type: Review

References (62)

1. Cummings JL. Alzheimer's disease. N Engl J Med 2004 ; 351 : 56-67
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6 • An excellent overview of the amyloid hypothesis of AD.
3. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003 ; 43 : 545-584 (Pubitemid 37372653)
4. Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J Clin Invest 2005 ; 115 : 1121-1129 (Pubitemid 40629026)
5. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory defi cits, A β elevation, and amyloid plaques in transgenic mice. Science 1996 ; 274 : 99-102 • A seminal demonstration of cognitive function loss in an animal model of AD.
6. Frost D, Gorman PM, Yip CM, Chakrabartty A. Co-incorporation of A β 40 and A β 42 to form mixed pre-fi brillar aggregates. Eur J Biochem 2003 ; 270 : 654-663
7. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003 ; 100 : 10417-10422 (Pubitemid 37071893)
8. Le Corre S, Klafki HW, Plesnila N, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 2006 ; 103 ; 9673-9678 (Pubitemid 43955883)
9. Chauhan NB, Siegel GJ, Feinstein DL. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology 2005 ; 48 : 93-104 (Pubitemid 40022919)
10. Walker LC, Ibegbu CC, Todd CW, et al. Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochem Pharmacol 2005 ; 69 : 1001-1008 (Pubitemid 40349014)
11. Anderson JJ, Holtz G, Baskin PP, et al. Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 2005 ; 69 : 689-698
12. Barten DM, Guss VL, Corsa JA, et al. Dynamics of β-amyloid reductions in brain, cerebrospinal fl uid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. J Pharmacol Exp Ther 2005 ; 312 : 635-643 (Pubitemid 40189561)
13. Best JD, Jay MT, Otu F, et al. In vivo characterisation of Aβ (40) changes in brain and CSF using the novel γ-secretase inhibitor N-[cis-4-[(4-chlorophenyl) sulfonyl]-4-(2,5-difluorophenyl) cyclohexyl]-1,1,1- trifluoromethane sulfonamide (MRK-560) in the rat. J Pharmacol Exp Ther 2006 ; 317 : 786-790
14. Wang Y, Chan SL, Miele L, et al. Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci USA 2004 ; 101 : 9458-9462 (Pubitemid 38812896)
15. Curry CL, Reed LL, Golde TE, et al. Gamma secretase inhibitor blocks notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005 ; 24 : 6333-6344 (Pubitemid 41486467)
16. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004 ; 279 : 12876-12882 (Pubitemid 38445862)
17. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid βconcentrations after administration of a γ-secretase inhibitor in volunteers. Clin Neuropharmacol 2005 ; 28 : 126-132 (Pubitemid 40923411)
18. Siemers E, Quinn J, Kaye J, et al. Effect of LY450139, a functional γ-secretase inhibitor, on plasma and cerebrospinal fl uid concentrations A β and cognitive functioning in patients with mild to moderate Alzheimer's disease. Neurology 2004 ; 62 (suppl 5): A174
19. Luo Y, Bolon B, Damore MA, et al. BACE1 (γ-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 2003 ; 14 : 81-88 (Pubitemid 37103182)
20. Wong P. BACE. Alzheimer Demen 2005 ; 1 (Suppl 1): S3
21. Citron M. γ-Secretase inhibition for the treatment of Alzheimer's disease: promise and challenge. Trends Pharmacol Sci 2004 ; 25 : 92-97 (Pubitemid 38183395)
22. Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001 ; 8 (Suppl 1): 28-35 (Pubitemid 32889453)
23. Gibson GL, Douraghi-Zadeh D, Parsons RB, et al. Properties of ovine colostrinin (O-CLN) on the in vitro aggregation and toxicity of β-amyloid. Neurobiol Aging 2004 ; 25 (Suppl 2): S592
24. Bilikiewicz A, Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimer's Dis 2004 ; 6 : 17-26 (Pubitemid 38418554)
25. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (Clioquinol) targeting A β amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 2003 ; 60 : 1685-1691 (Pubitemid 37521621)
26. McLaurin J, Golomb R, Jurewicz A, et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit a β-induced toxicity. J Biol Chem 2000 ; 275 (24): 18495-18502 (Pubitemid 30414810)
27. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006 ; 6 : 404-416
28. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004 ; 89 : 807-811 (Pubitemid 38684728)
29. Gandy S, Martins RN, Buxbaum J. Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2003 ; 17 : 259-266 (Pubitemid 37521282)
30. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 : 173-177 (Pubitemid 29327547)
31. Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 2000 ; 408 : 979-982 (Pubitemid 32101644)
32. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000 ; 408 : 982-985 (Pubitemid 32101645)
33. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003 ; 61 : 46-54 (Pubitemid 36818745)
34. Dolphin PJ. Lipoprotein metabolism and the role of apolipoproteins as metabolic programmers. Can J Biochem Cell Biol 1985 ; 63 (8): 850-869 • An in-depth review of lipoprotein metabolism, apolipoprotein structure and function.
35. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986 ; 232 (4746): 34-47• An excellent review of the lipid transport pathways.
36. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994 ; 63 : 601-637 (Pubitemid 2109131)
37. Bjorkhem I, Meany S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004 ; 24 (5): 806-815 • Excellent review of brain cholesterol metabolism.
38. Hirsch-Reinshagen V, Wellington CL. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr Opin Lipidol 2007 ; 18 (3): 325-332 (Pubitemid 46743058)
39. Cedazo-Mínguez A, Cowburn RF. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med 2001 ; 5 (3): 254-266
40. Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 2005 ; 46 (5): 949-968 (Pubitemid 43309219)
41. Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann NY Acad Sci 2000 ; 924 : 81-90
42. Sadowski MJ, Pankiewicz J, Scholtzova H, et al. Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci USA 2006 ; 103 (49): 18787-18792 (Pubitemid 44913488)
43. Deane R, Sagare A, Hamm K, et al. ApoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest 2008 ; 118 : 4002-4013
44. Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Aβ. Neuron 2008 ; 58 (5): 681-693 (Pubitemid 351778466)
45. Masse I, Bordet R, Deplanque D, et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005 ; 76 : 1624-1629 (Pubitemid 41697623)
46. Miida T, Takahashi A, Tanabe N, Ikeuchi T. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression? Curr Opin Lipidol 2005 ; 16 (6): 619-623
47. Schneider A, Schulz-Schaeffer W, Hartmann T, et al. Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol Dis 2006 ; 23 : 573-577 (Pubitemid 44234093)
48. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 2001 ; 98 (10): 5856-5861 (Pubitemid 32435732)
49. Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinfl ammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007 ; 104 (25): 10601-10606 (Pubitemid 47185711)
50. Koldamova R, Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease-implications for a new therapeutic approach. Curr Alzheimer Res 2007 ; 4 (2): 171-178 (Pubitemid 46557507)
51. Riddell DR, Zhou H, Comery TA, et al. The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci 2007 ; 34 (4): 621-628 (Pubitemid 46483091)
52. Huttunen HJ, Kovacs DM. ACAT as a drug target for Alzheimer's disease. Neurodegener Dis 2008 ; 5 (3-4): 212-214 (Pubitemid 351347853)
53. Wang SS, Chen YT, Chou SW. Inhibition of amyloid fibril formation of β-amyloid peptides via the amphiphilic surfactants. Biochim Biophys Acta 2005 ; 1741 : 307-313 (Pubitemid 41338676)
54. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993 ; 342 : 697-699
55. Dodart JC, Marr RA, Koistinaho M, et al. Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2005 ; 102 : 1211-1216 (Pubitemid 40170751)
56. Olesen OF, Dagø L. High density lipoprotein inhibits assembly of amyloid β-peptides into fi brils. Biochem Biophys Res Commun 2000 ; 270 (1): 62-66 (Pubitemid 30440393)
57. Biere AL, Ostaszewski B, Stimson ER, et al. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996 ; 271 (51): 32916-32922 (Pubitemid 27008725)
58. Deane R, Wu Z, Sagare A, et al. LRP/amyloid β-peptide interaction mediates differential brain effl ux of Aβ isoforms. Neuron 2004 ; 43 : 333-344 (Pubitemid 39061126)
59. Cam JA, Bu G. Modulation of β-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener 2006 ; 1 : 8. Published online 18 August 2006, doi:10.1186/1750-1326-1-8 (Pubitemid 46724551)
60. Kang DE, Pietrzik CU, Baum L, et al. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000 ; 106 : 1159-1166 (Pubitemid 30835017)
61. Kang DE, Saitoh T, Chen X, et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset alzheimer's disease. Neurology 1997 ; 49 : 56-61 (Pubitemid 27328682)
62. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000 ; 106 : 1489-1499 (Pubitemid 32038587)